Celcuity Takes Major Step in Cancer Therapy Development
Celcuity Inc. recently reached a significant milestone as it completed the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for gedatolisib, an innovative treatment for advanced breast cancer that is hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-). This submission comes at a time when many are seeking advancements in oncology therapies that are more targeted and effective.
Details of the New Drug Application
The NDA was submitted under the FDA's Real-Time Oncology Review (RTOR) program, a streamlined process designed to accelerate the review of promising cancer therapies. Celcuity hopes this initiative will shorten the duration between drug submission and potential market availability. Gedatolisib has previously earned the prestigious Breakthrough Therapy and Fast Track designations due to its encouraging results in preliminary clinical studies.
Clinical Trial Insights
The NDA submission is rooted in compelling data gathered from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial. The results showcased that patients treated with a combination therapy of gedatolisib, fulvestrant, and palbociclib experienced a remarkable reduction in the risk of disease progression or death by an impressive 76% compared to those receiving fulvestrant alone. In quantitative terms, this led to a substantial increase in median progression-free survival (PFS) — 9.3 months for the gedatolisib combination versus just 2.0 months for fulvestrant, representing a 7.3-month improvement.
Significance of Gedatolisib
Gedatolisib is a novel investigational agent that functions as a multi-target inhibitor acting on the PI3K/AKT/mTOR (PAM) signaling pathway. Unlike many current therapies that focus on single-target inhibition, gedatolisib’s broad mechanism targets multiple components of the PAM pathway simultaneously. This kind of comprehensive action is vital, as focusing on just one component can result in compensatory pathways becoming activated, potentially minimizing a treatment's effectiveness.
Understanding the Real-Time Oncology Review Program
Beyond the specifics of gedatolisib, it's essential to understand the operational mechanisms of the RTOR program. Founded by the FDA, this program allows for a more efficient review process of new cancer drugs, ultimately aiming to make effective therapies available to patients sooner. To be eligible for RTOR, a drug must demonstrate significant clinical utility across well-controlled investigations, clear trial endpoint interpretations, and no aspects that are likely to prolong review timelines.
About Celcuity Inc.
Celcuity, a clinical-stage biotechnology firm, is focused on developing targeted therapies that address several solid tumor types. With gedatolisib being its lead candidate, the company aims to change the landscape of breast cancer treatment. The VIKTORIA-1 trial, which evaluates gedatolisib alongside fulvestrant and palbociclib, has successfully completed patient enrollment. In parallel, the ongoing VIKTORIA-2 trial seeks to explore the efficacy of gedatolisib in combination with other therapies corresponding to HR+/HER2- advanced breast cancer.
Future Clinical Studies
In addition to its key trials, Celcuity is also progressing with the CELC-G-201 trial, assessing gedatolisib mixed with darolutamide in individuals with metastatic castration-resistant prostate cancer. This illustrates the company’s broader commitment to finding effective solutions across different cancer types.
Frequently Asked Questions
What is gedatolisib?
Gedatolisib is an investigational cancer therapy designed to inhibit multiple components of the PI3K/AKT/mTOR pathway, aiming to improve patient outcomes in breast cancer treatment.
What designations has gedatolisib received?
Gedatolisib has received Breakthrough Therapy and Fast Track designations from the FDA, reflecting its potential in cancer treatment.
What is the significance of the Real-Time Oncology Review program?
The RTOR program from the FDA is intended to expedite the review process for promising cancer therapies, potentially allowing patients to access new treatments quicker.
In which clinical trials is Celcuity currently engaged?
Celcuity is conducting several clinical trials, including the VIKTORIA-1 trial focusing on gedatolisib in advanced breast cancer, and the CELC-G-201 trial exploring its use in prostate cancer.
How does gedatolisib differ from single-target inhibitors?
Unlike single-target inhibitors that can lead to compensatory activation of uninhibited pathways, gedatolisib inhibits multiple components simultaneously, which allows for a more comprehensive blockade of cancer-promoting pathways.
